Trial Profile
A Phase II Study of Thiotepa Added to Fludarabine and Melphalan as the Preparative Regime for Alternative Donor Transplantation
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Thiotepa (Primary) ; Fibroblast growth factor 7; Fludarabine; Melphalan
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Lymphoid leukaemia; Myelodysplastic syndromes; Myelofibrosis; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 08 Dec 2023 Planned End Date changed from 1 Dec 2025 to 9 Jun 2025.
- 08 Dec 2023 Planned primary completion date changed from 1 Dec 2023 to 9 Jun 2024.
- 05 Jun 2023 Planned End Date changed from 1 Jun 2025 to 1 Dec 2025.